<DOC>
<DOCNO>EP-0614457</DOCNO> 
<TEXT>
<INVENTION-TITLE>
LEUKOTRIENE-B 4? DERIVATIVES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P1108	A61K31075	C07C31100	A61P3700	A61K31341	C07C69734	C07C69675	A61K31195	A61P2716	C07D30700	A61P3500	A61K3121	A61K31045	A61P100	A61K3134	A61K3119	C07C6928	C07C6900	A61K4740	A61P2900	C07C4300	C07C23500	C07D30900	C07C23520	C07C51347	C07C31151	A61K3134	C07C4313	C07D30733	A61K31341	A61K3122	A61K31045	C07C51353	A61P1100	A61K4740	A61P2900	C07C5900	C07C32310	A61P100	A61P1700	C07C32300	A61P3100	A61K31075	A61P3500	A61K31095	C07C5946	C07C40500	A61K3110	A61K31185	C07C43178	A61P1700	C07C40500	A61P2700	C07D30930	A61P1100	C07C69708	C07C69732	A61P3104	A61P3708	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	C07C	A61P	A61K	C07C	C07C	A61K	A61P	C07D	A61P	A61K	A61K	A61P	A61K	A61K	C07C	C07C	A61K	A61P	C07C	C07C	C07D	C07C	C07C	C07C	A61K	C07C	C07D	A61K	A61K	A61K	C07C	A61P	A61K	A61P	C07C	C07C	A61P	A61P	C07C	A61P	A61K	A61P	A61K	C07C	C07C	A61K	A61K	C07C	A61P	C07C	A61P	C07D	A61P	C07C	C07C	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P11	A61K31	C07C311	A61P37	A61K31	C07C69	C07C69	A61K31	A61P27	C07D307	A61P35	A61K31	A61K31	A61P1	A61K31	A61K31	C07C69	C07C69	A61K47	A61P29	C07C43	C07C235	C07D309	C07C235	C07C51	C07C311	A61K31	C07C43	C07D307	A61K31	A61K31	A61K31	C07C51	A61P11	A61K47	A61P29	C07C59	C07C323	A61P1	A61P17	C07C323	A61P31	A61K31	A61P35	A61K31	C07C59	C07C405	A61K31	A61K31	C07C43	A61P17	C07C405	A61P27	C07D309	A61P11	C07C69	C07C69	A61P31	A61P37	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Leukotriene-B4 derivatives have the formula (I), in which R
<
1
>
 stands for CH2OH, CH3, CF3, COOR
<
5
>
, CONR
<
6
>
R
<
7
>
, or R
<
1
>
 represents together with R
<
2
>
 a carbonyl group; R
<
2
>
 and R
<
3
>
 are different or the same and stand for H or an organic acid residue with 1-15 C atoms; R
<
4
>
 stands for H, C1-C10-alkyl, possibly substituted one or several times by chlorine or bromine, C3-C10-cycloalkyl, a C6-C10-aryl residue possibly independently substituted one or several times by chlorine, bromine, phenyl, C1-C4-alkyl, C1-C4-alkoxy, fluoromethyl, chloromethyl, trifluoromethyl, carboxy or hydroxy or a 5-6 membered aromatic heterocyclic ring with at least 1 heteroatom; R
<
5
>
 stands for hydrogen, C1-C10-alkyl, C3-C10-cycloalkyl, an aryl residue possibly substituted by 1-3 chlorine, bromine, phenyl, C1-C4-alkyl, C1-C4-alkoxy, fluoromethyl, chloromethyl, trifluoromethyl, carboxy or hydroxy, CH2-CO-(C6-C10)aryl or a 5-6 membered ring with at least 1 heteroatom; A stands for a trans, trans-CH=CH-CH=CH, -CH2CH2-CH=CH- or a tetramethylene group; B stands for a straight or branched chain C1-C10alkylene group, possibly substituted with fluorine or the group (a); D is a direct bond, oxygen, sulphur, -C=C-, -CH=CR
<
8
>
 or it may represent together  with B a direct bond; R
<
6
>
 and R
<
7
>
 are different or the same and stand for H or C1-C4-alkyl or R
<
7
>
 stands for H and R
<
6
>
 stands for C1-C10-alkanoyl or C1-C10-alkansulphonyl; R
<
8
>
 stands for H, C1-C5-alkyl, chlorine, bromine; m stands for the digits 1 or 4 and n equals 3-5. Also disclosed are the salts of these derivates with physiologically tolerable bases, when R
<
5
>
 stands for hydrogen, and their cyclodextrine clathrates.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SCHERING AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SCHERING AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUCHMANN BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
FROEHLICH WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
GIESEN CLAUDIA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEINDL JOSEF
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
BUCHMANN, BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT, ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
FROEHLICH, WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
GIESEN, CLAUDIA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEINDL, JOSEF
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA, WERNER
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Leucotriene B
4
 derivatives of the formula I 

 
wherein 


R
1
represents CH
2
OH, CH
3
, CF
3
, COOR
5
, CONR
6
R
7
 or 
R
1
together with R
2
 represents a carbonyl group, 
R
2
 and R
3
are identical or different and represent H or 
an organic acid radical having 1-15 carbon atoms, 
R
4
represents H, (C
1
-C
10
) alkyl optionally mono- or polysubstituted 
by chlorine or bromine; C
3
-C
10
 cycloalkyl; 
a C
6
-C
10
 aryl radical optionally mono- or polysubstituted 
by chlorine, bromine, phenyl, C
1
-C
4
-alkyl, 
C
1
-C
4
-alkoxy, fluoromethyl, chloromethyl, trifluoromethyl, 
carboxy or hydroxy independently of one 

another; or a 5- or 6-membered aromatic heterocyclic 
ring having at least 1 hetero atom, 
R
5
represents hydrogen, C
1
-C
10
 alkyl, C
3
-C
10
 cycloalkyl, 
a C
6
-C
10
 aryl radical optionally substituted by 1-3 
chlorine, bromine, phenyl, C
1
-C
4
-alkyl, C
1
-C
4
-alkoxy, 
fluoromethyl, chloromethyl, trifluoromethyl, carboxy 

or hydroxy substituent(s), CH
2
-CO-(C
6
-C
10
) aryl or a 
5- or 6-membered ring having at least 1 hetero atom, 
A
represents a 
trans
,
trans
-CH=CH-CH=CH-, a 
-CH
2
CH
2
-CH=CH- or a tetramethylene group, 
B
represents a straight-chain or branched-chain alkylene 
group that may optionally be substituted by fluorine  

 
or represents the group 


D
may represent a direct bond, oxygen, sulphur, -Câ‰¡C-, 
-CH=CR
8
-, or together with 
B
also a direct bond, 
R
6
 and R
7
are identical or different and represent H or 
C
1
-C
4
 alkyl or R
7
 represents H and R
6
 represents 
C
1
-C
10
-alkanoyl or C
1
-C
10
-alkanesulphonyl, 
R
8
represents H, C
1
-C
5
 alkyl, chlorine, bromine, 
m
represents the numbers 1 or 4 and 
n
is 3-5, 
 
and, when R
5
 represents hydrogen, the salts thereof with 
physiologically tolerable bases and the cyclodextrin 

clathrates thereof. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentan-1-ol. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentan-1-ol. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic  

 
acid. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentan-1-ol. 
(+/-)-(5RS)-5-hydroxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid methyl ester. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid methyl ester. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid tris-(hydroxymethyl)-aminomethane salt. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid 1,5-lactone. 
Pharmaceutical preparations, characterised by a 
content of one or two leucotriene B
4
 derivatives according 
to claims 1 to 14. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentan-1-ol.  

 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-acetoxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
cis
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cyclobutyl]-pentan-1-ol. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentan-1-ol. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid. 
(+/-)-(5RS)-5-hydroxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic  

 
acid 1,5-lactone. 
(+/-)-(5RS)-5-acetoxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-acetoxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid methyl ester. 
(+/-)-(5RS)-5-hydroxy-5-[
trans
-(2RS)-2-((1E,3E)-(5RS)-5-hydroxy-1,3-tridecadienyl)-(1RS)-cycloheptyl]-pentanoic 

acid tris-(hydroxymethyl)-aminomethane salt. 
Pharmaceutical preparations, characterised by one or 
two leucotriene B
4
 derivatives according to claims 1 to 
28. 
Process for the manufacture of leucotriene B
4
 
derivatives of the formula I according to patent claim 1, 

characterised in that an aldehyde of the formula II 

 
wherein m, A, B, D, R
3
 and R
4
 have the meanings given 
above, is reacted, optionally after protection of free 

hydroxy groups, with an organomagnesium compound of the 
formula III 


X-Mg-CH
2
-CH
2
-CH
2
-CH
2
-R
9
 
wherein X represents chlorine, bromine or iodine and R
9
 
represents -CH
3
, CF
3
 or -OR
10
 wherein R
10
 represents a 
readily removable ether radical and, optionally, subsequently 

in any desired sequence isomers are separated,  
 

protected hydroxy groups are freed and/or a free hydroxy 
group is esterified and/or the 1-hydroxy group is 

oxidised to the carboxylic acid and/or double bonds are 
hydrogenated and/or an esterified carboxy group (R
1
 = 
COOR
5
) is hydrolysed and/or reduced and/or a carboxy 
group (R
5
 = H) is esterified and/or a free carboxy group 
(R
5
 = H) is converted into an amide (R
1
 = CONHR
6
R
7
), or a 
carboxy group is converted into a salt with a physiologically 

tolerable base. 
</CLAIMS>
</TEXT>
</DOC>
